Bronchiectasis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Bronchiectasis Market Report Overview

The Bronchiectasis market across the 8MM (US, France, Germany, Italy, Spain, UK, Japan, and China) was valued at $1.4 billion in 2023 and the market will grow at a CAGR of more than 3% from 2023 to 2033. The 7MM (China, Japan, the United Kingdom, Spain, Italy, Germany, France, and the US). The market growth is attributed to the launch of brensocatib and an increase in the number of diagnosed prevalent cases of bronchiectasis.

Bronchiectasis Market Outlook 2023-2033 ($ Billion)

Bronchiectasis Market Outlook 2023-2033 ($ Billion)

Buy the Full Report to Know More About the Bronchiectasis Market Forecast
Download a Free Sample Report

The Bronchiectasis market research report offers an overview of Bronchiectasis, including its epidemiology, symptoms, diagnosis, and disease management. The report covers key topics, including strategic competitor assessment and market characterization that will help in identifying smart business strategies. In addition, the report’s data on unmet needs and clinical trial mapping will assist in understanding market gaps and making actionable predictions.

Market Size (2023) $1.4 billion
CAGR (2023-2033) >3%
Key Countries (8MM) ·       China

·       Japan

·       The United Kingdom

·       Spain

·       Italy

Key Drug Classes ·       Antibiotics

·       Mucolytics

·       Bronchodilators

·       Asthma Biologics

·       Inhaled Steroids

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Bronchiectasis Market Dynamics

There is a need to improve diagnosis so that patients can receive a diagnosis earlier and without the need for a computed tomography (CT) scan. This could be done through the identification of diagnostic biomarkers and greater awareness in the medical community. The bronchiectasis market will see continued usage of symptomatic drug classes such as antibiotics, mucolytics, and bronchodilators due to the lack of available disease-modifying treatments. Polypharmacy is common in bronchiectasis owing to which many patients are prescribed multiple classes for combined use such as an antibiotic combined with a mucolytic or a long- or short-acting bronchodilator. This, in turn, will propel the market growth during the forecast period.

Buy the Full Report for Additional Insights on the Key Bronchiectasis Market Dynamics
Download a Free Sample Report

Bronchiectasis Market Segmentation by Country

The key countries in the Bronchiectasis market are China, Japan, the United Kingdom, Spain, and Italy. In 2023, China accounted for the highest share of the total Bronchiectasis market. The dominance of China within the 8MM is because of the large bronchiectasis populations and higher drug prices. Additionally, China is the only country that has an additional pipeline agent (itobramycin) that is anticipated to launch during the forecast period.

Bronchiectasis Market Analysis by Country, 2023 (%)

Bronchiectasis Market Analysis by Country, 2023 (%)

Buy the Full Report for Country-Wise Insights on the Bronchiectasis Market

Download a Free Sample Report

Bronchiectasis Market Segmentation by Drug Classes

In 2023, there were several drug classes in the Bronchiectasis market including antibiotics, mucolytics, bronchodilators, asthma biologics, and inhaled steroids among others. In 2023, the antibiotics drug class was the leading revenue generator in the Bronchiectasis market. Antibiotics are commonly used off-label to treat bronchiectasis patients whose lungs are colonized with bacteria as a prophylactic treatment or to treat lung infections. They can be administered through the oral, intravenous (IV), or inhaled routes of administration depending on the severity and type of bacteria.

Bronchiectasis Market Analysis by Drug Classes, 2023 (%)

Bronchiectasis Market Analysis by Drug Classes, 2023 (%

Buy the Full Report for Drug-Class Insights on the Bronchiectasis Market

Download a Free Sample Report

Segments Covered in this Report

Bronchiectasis Market Country Outlook ($ Billion, 2023-2033)

  • China
  • Japan
  • The United Kingdom
  • Spain
  • Italy

Bronchiectasis Market Drug Classes Outlook (%, 2023-2033)

  • Antibiotics
  • Mucolytics
  • Bronchodilators
  • Asthma Biologics
  • Inhaled Steroids


  • Overview of Bronchiectasis, including epidemiology, symptoms, diagnosis, and disease management.
  • Annualized Bronchiectasis therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the Bronchiectasis therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for Bronchiectasis treatment. The most promising candidates in Phase III and Phase IIb development are profiled.
  • Analysis of the current and future market competition in the global Bronchiectasis therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Key Highlights

Report deliverables include a PowerPoint report and Excel-based forecast model

Forecasts includes the 8MM

Forecasts covers from 2023-2033

Reasons to Buy

  • Review the pipeline products and technologies and identify the companies with the most robust pipeline to develop and design your in-licensing and out-licensing strategies.
  • Understand the trends shaping and driving the Bronchiectasis therapeutics market to develop business strategies.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the GD therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
  • Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Boehringer Ingelheim
Chiesi Farmaceutici
Haisco Pharmaceutical
Metagone Biotech
Suzhou Regend Therapeutics
BioAegis Therapeutics
Reistone Biopharma
Shanghai Fosun Pharmaceutical (Group) Co Ltd

Table of Contents

Table of Contents (PowerPoint Deck)

1. Preface

1.1. Contents

1.2. Abbreviations

1.3. Related Reports

2. Executive Summary

3. Disease Overview

3.1. Overview of Bronchiectasis

3.2. Bronchiectasis SWOT Analysis

3.3. Pathophysiology of Bronchiectasis

3.4. Classification of Bronchiectasis

4. Epidemiology

4.1. Total Prevalent Cases of Bronchiectasis, Both Sexes, Ages ≥18 Years, 2023-33

4.2. Total Prevalent Cases of Bronchiectasis, Both Sexes, Ages ≥18 Years, 2023–33

4.3. Age-Specific Trends in Diagnosed Prevalent Cases of Bronchiectasis, Both Sexes, 2023

4.4. Sex-Specific Diagnosed Prevalent Cases of Bronchiectasis, Both Sexes, Ages ≥18 Years, 2023

4.5. Diagnosed Prevalent Cases of Bronchiectasis By Severity, Both Sexes, Ages ≥18 Years, 2023

4.6. Sources and Methodology for Diagnosed Prevalence of Bronchiectasis

5. Current Treatment Options

5.1. Treatment Paradigm

5.2. Marketed Products

5.3. Product Profile: Antibiotics (Oral, IV, Inhaled)

5.4. Product Profile: Bronchitol

5.5. Product Profile: Hypertonic Saline

5.6. Product Profile: Mucolytics

5.7. Product Profile: Bronchodilators

5.8. Product Profile: Asthma Biologics

5.9. Product Profile: Inhaled Steroids

6. Unmet Needs and Opportunities

6.1. Unmet Needs in Bronchiectasis

6.2. Increased Awareness and Education

6.3. Improved Diagnostic Methods

6.4. Lack of Approved Therapies

6.5. Targets for Improved Therapies

7. R&D Strategies

7.1. Trends in Clinical Trial Design in Bronchiectasis

7.2. Trends in Deal-Making in Bronchiectasis

8. Pipeline Assessment

8.1. Bronchiectasis Pipeline Overview

8.2. Late-Stage Pipeline Agents for Bronchiectasis

8.3. Product Profile: Insmed’s Brensocatib

8.4. Bronchiectasis: Clinical Trials – Phase II and Phase III Overview

9. Market Outlook

9.1. Bronchiectasis Market Forecast

9.2. Market Drivers and Barriers

10. Appendix

10.1. Primary Research: KOL Information

10.2. Bibliography

10.3. About the Authors

11. Contact Us

Frequently asked questions

Bronchiectasis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033 standard reports
Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Bronchiectasis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Bronchiectasis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033 in real time.

  • Access a live Bronchiectasis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.